HSIC Quote, Financials, Valuation and Earnings

Intelligent Bio Solutions has a net margin of 2.95% compared to Henry Schein's net margin of -370.29%. Henry Schein's return on equity of 7.8% beat Intelligent Bio Solutions's return on equity of -164.63%.

Henry Schein has a consensus price target of $79.38, signalling upside risk potential of 21.25%. On the other hand Intelligent Bio Solutions has an analysts' consensus of -- which suggests that it could grow by 788.89%. Given that Intelligent Bio Solutions has higher upside potential than Henry Schein, analysts believe Intelligent Bio Solutions is more attractive than Henry Schein.

Henry Schein has a beta of 0.844, which suggesting that the stock is 15.587% less volatile than S&P 500. In comparison Intelligent Bio Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Henry Schein has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Henry Schein pays -- of its earnings as a dividend. Intelligent Bio Solutions pays out -- of its earnings as a dividend.

Henry Schein quarterly revenues are $3.2B, which are larger than Intelligent Bio Solutions quarterly revenues of $607.5K. Henry Schein's net income of $94M is higher than Intelligent Bio Solutions's net income of -$2.2M. Notably, Henry Schein's price-to-earnings ratio is 21.54x while Intelligent Bio Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Henry Schein is 0.66x versus 1.55x for Intelligent Bio Solutions. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of 2.95% compared to Henry Schein's net margin of -72.93%. Henry Schein's return on equity of 7.8% beat Standard BioTools's return on equity of -36.54%.

Henry Schein has a consensus price target of $79.38, signalling upside risk potential of 21.25%. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 121.96%. Given that Standard BioTools has higher upside potential than Henry Schein, analysts believe Standard BioTools is more attractive than Henry Schein.

Henry Schein has a beta of 0.844, which suggesting that the stock is 15.587% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.541, suggesting its more volatile than the S&P 500 by 54.101%.

Henry Schein has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Henry Schein pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

Henry Schein quarterly revenues are $3.2B, which are larger than Standard BioTools quarterly revenues of $46.7M. Henry Schein's net income of $94M is higher than Standard BioTools's net income of -$34.1M. Notably, Henry Schein's price-to-earnings ratio is 21.54x while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Henry Schein is 0.66x versus 2.17x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR has a net margin of 2.95% compared to Henry Schein's net margin of -111.78%. Henry Schein's return on equity of 7.8% beat LENSAR's return on equity of -134.77%.

Henry Schein has a consensus price target of $79.38, signalling upside risk potential of 21.25%. On the other hand LENSAR has an analysts' consensus of $15.00 which suggests that it could grow by 8.3%. Given that Henry Schein has higher upside potential than LENSAR, analysts believe Henry Schein is more attractive than LENSAR.

Henry Schein has a beta of 0.844, which suggesting that the stock is 15.587% less volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Henry Schein has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Henry Schein pays -- of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend.

Henry Schein quarterly revenues are $3.2B, which are larger than LENSAR quarterly revenues of $16.7M. Henry Schein's net income of $94M is higher than LENSAR's net income of -$18.7M. Notably, Henry Schein's price-to-earnings ratio is 21.54x while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Henry Schein is 0.66x versus 2.98x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.

Patterson Companies has a net margin of 2.95% compared to Henry Schein's net margin of 1.99%. Henry Schein's return on equity of 7.8% beat Patterson Companies's return on equity of 14.22%.

Henry Schein has a consensus price target of $79.38, signalling upside risk potential of 21.25%. On the other hand Patterson Companies has an analysts' consensus of $30.42 which suggests that it could fall by -1.69%. Given that Henry Schein has higher upside potential than Patterson Companies, analysts believe Henry Schein is more attractive than Patterson Companies.

Henry Schein has a beta of 0.844, which suggesting that the stock is 15.587% less volatile than S&P 500. In comparison Patterson Companies has a beta of 0.731, suggesting its less volatile than the S&P 500 by 26.948%.

Henry Schein has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Patterson Companies offers a yield of 3.36% to investors and pays a quarterly dividend of $0.26 per share. Henry Schein pays -- of its earnings as a dividend. Patterson Companies pays out 52.89% of its earnings as a dividend. Patterson Companies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Henry Schein quarterly revenues are $3.2B, which are larger than Patterson Companies quarterly revenues of $1.6B. Henry Schein's net income of $94M is higher than Patterson Companies's net income of $31.3M. Notably, Henry Schein's price-to-earnings ratio is 21.54x while Patterson Companies's PE ratio is 20.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Henry Schein is 0.66x versus 0.42x for Patterson Companies. Usually stocks with elevated PS ratios are considered overvalued.